-
Mashup Score: 3Sustained remissions in CLL after frontline FCR treatment with very long-term follow-up - 8 month(s) ago
Key Points. Patients (pts) with mutated IGHV (IGHV-M) have favorable very long-term PFS after FCR, although late relapse (>10 years) rarely occursCumulative
Tweet
-
Mashup Score: 0
The CLL14 study (NCT02242942) explored the activity of obinutuzumab (anti-CD20) plus venetoclax (Bcl2 inhibitor) versus obinutuzumab plus chlorambucil in patients with previously untreated chronic lymphocytic leukemia (CLL). Here the authors report the 5-year long-term results of the clinical trial and transcriptional profiles associated with response to therapies.
Tweet-
Othman Al-Sawaf from Germany highlighted updated 5-year data from the CLL14 trial of 1 year fixed duration venetoclax-obinutuzumab versus chlorambucil-obinutuzumab in patients with untreated CLL, recently published in nature communications. At 5 years after randomization, the estimated PFS rate is 62.6% after Ven-Obi and 27.0% after Clb-Obi.
-
-
Mashup Score: 7
In this episode, we take a deep dive into the management of newly diagnosed CLL with Dr. Nitin Jain from MD Anderson and discuss key clinical trials in the past decade that has shaped the current treatment paradigm.
Tweet-
Nitin Jain from MD Anderson Cancer Center gave a great round up in the 'next questions' session at #SOHO23 focusing on next questions in CLL. Check out our episode with Dr Jain on Blood Cancer Talks where we chatted about updates in newly-diagnosed CLL.
-
-
Mashup Score: 4
TP53 aberrations [del(17p) or TP53 mutation] predict poor survival with chemoimmunotherapy in patients with chronic lymphocytic leukaemia (CLL).
Tweet-
Dr. Al-Sawaf also highlighted this pooled analysis of 89 patients across 4 clinical trials looking at the efficacy of first-line ibrutinib for patients with CLL with TP53 aberrations, published in the British Journal of Haematology. With a median follow-up of 49·8 months, median PFS was not reached. PFS and OS rate at four years were 79% and 88%, respectively.
-
-
Mashup Score: 0
Patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma for whom treatment has failed with both Bruton tyrosine kinase (BTK) inhibitor and venetoclax have few treatment options and poor outcomes.
Tweet-
Tanya Siddiqi from City of Hope presented data from the TRANSCEND CLL 04 study of liso-cel CAR T-cells in patients with relapsed/refractory CLL at #SOHO23. Among 49 patients who had progressed following both BTKi and venetoclax and were treated at dose level 2, 18% achieved a CR and 24% achieved a PR. Intriguingly some patients with stable disease also achieved uMRD - a group in whom further investigation is required.
-
John Seymour from Australia highlighted at #SOHO23 that, for the right patient - that is, a patient <65 years with IGVH mutated and TP53 wild type disease - FCR can still be a valuable treatment option, with a cure fraction of about 50% at 15 years. tMN risk is about 2%.